Bromelains

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Bromelains is a protease indicated in the treatment of inflammation and for eschar removal.

Generic Name
Bromelains
DrugBank Accession Number
DB13281
Background

Bromelain is a protease enzyme derived from the stems of pineapples that is composed of a mixture of different thiol endopeptidases and other components like phosphatase, glucosidase, peroxidase, cellulase, escharase, and several protease inhibitors 2. It works by selectively inhibiting the biosynthesis of proinflammatory prostaglandins 1 and also has analgesic properties, as well as anticancerous and pro-apoptotic effects. Bromelain holds potential therapeutic effect as a treatment of conditions including angina pectoris, bronchitis, sinusitis, surgical trauma, and osteoarthritis. It is considered as a safe food supplement.

Type
Biotech
Groups
Investigational
Synonyms
  • Bromelain
  • Bromelain juice
  • Bromelain protease
  • Bromelaina
  • Bromelaines
  • Bromelains
  • Pineapple protease

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Symptomatic treatment ofSwelling••• ••••••••••••••• ••••••
Associated Therapies
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Bromanase 1800 Tab 225mgTablet225 mgOralNf Formulas Inc.1984-12-312000-06-21Canada flag
Bromelain 250Capsule250 mgOralThorne Research Inc.1984-12-312005-08-26Canada flag
Bromelain 500 (300gdu/capsule)Capsule500 mgOralQuest Vitamins A Div Of Purity Life Health Products1993-12-311999-08-30Canada flag
Bromelain 500mg TabletsTablet500 mgOralJamieson Laboratories Ltd1996-09-102000-09-08Canada flag
Bromelain Pineapple Enzyme 50 Mg Nu LifeTablet50 mgOralNu Life Nutrition Ltd.1963-12-312000-03-03Canada flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Alka-pan TabletsBromelains (50 mg) + Betaine hydrochloride (20 mg) + Ox bile extract (35 mg) + Pancrelipase (135 mg) + Papaya (125 mg)TabletOralMorter HealthsystemNot applicableNot applicableCanada flag
Body Tropics Plus TabBromelains (50 mg) + Choline bitartrate (500 mg) + Inositol (250 mg) + Pyridoxine (25 mg) + Racemethionine (100 mg)TabletOralPro Shop Inc.1994-12-312008-08-02Canada flag
Bromelain and Papain TabBromelains (75 mg) + Papain (35 mg)TabletOralVita Health Products Inc1978-12-312002-07-31Canada flag
Chewable Enzymes TabletsBromelains (15 mg) + Pancrelipase amylase (5 mg) + Papain (100 mg)TabletOralGahler Enterprises Ltd.1988-12-312002-07-17Canada flag
Cilobana Cpa TabBromelains (4 mg / tab) + Ascorbic acid (150 mg / tab) + Citrus bioflavonoids (75 mg / tab) + Hesperidin (75 mg / tab) + Vitamin A (10000 unit / tab)TabletOralAnabolic Laboratories Inc.1968-12-311996-10-02Canada flag

Categories

ATC Codes
D03BA03 — BromelainsM09AB03 — Bromelains
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
U182GP2CF3
CAS number
9001-00-7

References

General References
  1. Taussig SJ: The mechanism of the physiological action of bromelain. Med Hypotheses. 1980 Jan;6(1):99-104. [Article]
  2. Pavan R, Jain S, Shraddha, Kumar A: Properties and therapeutic application of bromelain: a review. Biotechnol Res Int. 2012;2012:976203. doi: 10.1155/2012/976203. Epub 2012 Dec 10. [Article]
  3. Brien S, Lewith G, Walker A, Hicks SM, Middleton D: Bromelain as a Treatment for Osteoarthritis: a Review of Clinical Studies. Evid Based Complement Alternat Med. 2004 Dec;1(3):251-257. Epub 2004 Oct 6. [Article]
  4. AIFA Product Information: NexoBrid (bromelain-enriched proteolytic enzymes) for topical use [Link]
PubChem Substance
347911446
RxNav
1752
Wikipedia
Bromelain

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedSupportive CareDental Decay / Plaque, Dental1
2Not Yet RecruitingTreatmentIrreversible Pulpitis (Toothache)1
2Not Yet RecruitingTreatmentMucinous Adenocarcinoma / Mucinous Tumor / Peritoneal Cancer / Pseudomyxoma Peritonei1
2Unknown StatusTreatmentCancer1
1Active Not RecruitingTreatmentPseudomyxoma Peritonei1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet, coatedOral
Tablet, coatedOral40 MG
TabletOral
TabletOral225 mg
CapsuleOral250 mg
CapsuleOral500 mg
TabletOral50 mg
PowderOral20 mg / g
TabletOral500 mg
Tablet, sugar coatedOral
PowderCutaneous2 G
PowderCutaneous5 G
Tablet, film coatedOral
Tablet, coatedOral
TabletOral100 mg / tab
CapsuleOral500 mg / cap
Tablet, delayed releaseOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at June 23, 2017 20:39 / Updated at March 29, 2024 03:23